Allan-Herndon-Dudley Syndrome

Allan-Herndon-Dudley Syndrome

Overview

Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked recessive disorder characterized by severe intellectual disability, dystonia, and alterations in thyroid hormone metabolism. The syndrome results from mutations in the SLC16A2 gene (also known as MCT8), which encodes a monocarboxylate transporter responsible for transporting thyroid hormones across the cell membrane. This condition primarily affects males and is considered a member of the thyroid hormone resistance syndromes[@friesema2004].

Genetics

AHDS is caused by loss-of-function mutations in the SLC16A2 gene (solute carrier family 16 member 2) located on chromosome Xq13.2. The gene encodes the thyroid hormone transporter MCT8 (monocarboxylate transporter 8), which is essential for the cellular uptake of active thyroid hormones T3 (triiodothyronine) and T4 (thyroxine)[@schwartz2005].

Inheritance Pattern

• X-linked recessive inheritance
• Primarily affects males
• Female carriers may exhibit mild thyroid dysfunction but are usually asymptomatic
• De novo mutations account for approximately 25% of cases

Known Mutations

Over 70 pathogenic variants have been identified, including:

• Missense mutations (most common)
• Nonsense mutations
• Frameshift mutations
• Splice site mutations

Pathophysiology

Thyroid Hormone Transport Defect

MCT8 is expressed in various tissues, including:

• Brain ([neurons](/entities/neurons), [astrocytes](/entities/astrocytes), choroid plexus)
• Liver
• Kidney
• Skeletal muscle
• Heart

...

Allan-Herndon-Dudley Syndrome

Overview

Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked recessive disorder characterized by severe intellectual disability, dystonia, and alterations in thyroid hormone metabolism. The syndrome results from mutations in the SLC16A2 gene (also known as MCT8), which encodes a monocarboxylate transporter responsible for transporting thyroid hormones across the cell membrane. This condition primarily affects males and is considered a member of the thyroid hormone resistance syndromes[@friesema2004].

Genetics

AHDS is caused by loss-of-function mutations in the SLC16A2 gene (solute carrier family 16 member 2) located on chromosome Xq13.2. The gene encodes the thyroid hormone transporter MCT8 (monocarboxylate transporter 8), which is essential for the cellular uptake of active thyroid hormones T3 (triiodothyronine) and T4 (thyroxine)[@schwartz2005].

Inheritance Pattern

• X-linked recessive inheritance
• Primarily affects males
• Female carriers may exhibit mild thyroid dysfunction but are usually asymptomatic
• De novo mutations account for approximately 25% of cases

Known Mutations

Over 70 pathogenic variants have been identified, including:

• Missense mutations (most common)
• Nonsense mutations
• Frameshift mutations
• Splice site mutations

Pathophysiology

Thyroid Hormone Transport Defect

MCT8 is expressed in various tissues, including:

• Brain ([neurons](/entities/neurons), [astrocytes](/entities/astrocytes), choroid plexus)
• Liver
• Kidney
• Skeletal muscle
• Heart

The loss of functional MCT8 transporter leads to:

Impaired neuronal thyroid hormone uptake — neurons cannot efficiently import T3, despite normal or elevated serum T3 levels

Elevated serum T3 — due to impaired cellular uptake and increased peripheral conversion

Reduced cerebral T3 — leading to impaired brain development and function

Abnormal thyroid function tests — elevated T3, normal or reduced T4, normal TSH

Neurodevelopmental Consequences

The thyroid hormone deficiency in the brain during critical developmental periods results in:

• Impaired neuronal migration
• Abnormal cortical development
• Disrupted myelination
• Altered synaptic plasticity
• Abnormal basal ganglia development (particularly affecting the globus pallidus)[@visser2009]

Clinical Features

Neurological

• Severe intellectual disability — IQ typically below 40
• Dystonia — progressive movement disorder, often beginning in childhood
• Ataxia — impaired coordination
• Hypotonia — decreased muscle tone in infancy
• Seizures — observed in approximately 30% of patients
• Delayed motor milestones
• Speech impairment — most patients remain non-verbal

Physical Features

• Microcephaly — small head circumference
• Facial dysmorphism — including elongated face, prominent ears, and nasal abnormalities
• Skeletal abnormalities — including kyphosis and joint contractures
• Growth retardation

Thyroid Function

• Elevated serum T3
• Normal or reduced T4
• Normal TSH (euthyroid)
• Inappropriately normal TSH despite elevated T3

Diagnosis

Clinical Diagnosis

Based on:

Clinical features (intellectual disability, dystonia, characteristic thyroid function abnormalities)

Family history (X-linked pattern)

Genetic testing confirming SLC16A2 mutation

Laboratory Findings

• Elevated serum T3 (often 2-3x normal)
• Normal or reduced free T4
• Normal TSH
• Normal thyroid antibodies (ruling out autoimmune thyroiditis)

Genetic Testing

• SLC16A2 sequencing — identifies pathogenic variants
• Multiplex ligation-dependent probe amplification (MLPA) — detects large deletions/duplications

Neuroimaging

• MRI findings may include:
• Cerebral atrophy
• Abnormal signal in the globus pallidus
• Delayed myelination
• Cerebellar atrophy (in some cases)

Management

Current Treatment Approaches

Thyroid hormone therapy — supraphysiological doses of T4 may provide some benefit[@grijse2020]

T3 supplementation — experimental approaches to bypass the transport defect

Dystonia management — baclofen, botulinum toxin injections, physical therapy

Antiepileptic drugs — for seizure control

Supportive care — speech therapy, occupational therapy, special education

Emerging Therapies

• Gene therapy — experimental approaches to restore MCT8 function[@patel2021]
• Thyroid hormone analogs — such as diiodothyropropionic acid (DITPA) that can enter cells via alternative transporters
• Cell-based therapies — under investigation

Multidisciplinary Care

• Neurology
• Endocrinology
• Genetics
• Developmental pediatrics
• Physical/occupational therapy
• Speech therapy

Epidemiology

• Prevalence: Extremely rare, estimated at <1:100,000 males
• Geographic distribution: Worldwide, with no ethnic predominance
• Onset: Present from birth, with symptoms becoming apparent in early infancy
• [Thyroid hormone resistance syndrome (RTHβ) — caused by THRB gene mutations](/genes/th)
• [X-linked psychomotor retardation — other forms](/genes/ar)
• [Dystonia-Parkinsonism syndromes](/genes/ar)

Research Directions

Understanding MCT8 substrate specificity — to develop targeted therapies

Gene therapy vectors — for efficient delivery to neurons

Thyroid hormone analog development — to bypass the transport defect

• Natural history studies — to better understand disease progression
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Friesema et al., MCT8 mutations and thyroid hormone transport (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15292051/)

[Schwartz et al., Allan-Herndon-Dudley syndrome phenotype (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15719197/)

[Visser et al., MCT8 deficiency: clinical spectrum (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19608652/)

[Grijse linkers et al., Thyroid hormone therapy in AHDS (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32251482/)

[Patel et al., Gene therapy for MCT8 deficiency (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34074890/)